Cost-effectiveness of Liple® (LipoPGE1) for arteriosclerosis obliterans patients in Japan: An economic evaluation using the EQ-5D instrument

International Angiology

Volumn 25, Issue 2, 2006, Pages 169-174

  Ikeda, S ^a   Kobayashi, M ^a   Fukuhara, S ^b   Esato, K ^c  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Yamaguchi Pref Central Hospital   (Japan)

Author keywords

Arteriosclerosis obliterans; Cost; Effectiveness; EQ 5D; LipoPGE1; Quality of life

Indexed keywords

LIPOPROSTAGLANDIN E1;

ADOLESCENT; ADULT; ARTICLE; CALCULATION; CLINICAL OBSERVATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; HUMAN; JAPAN; LIMB DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REST; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; ULCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; ARTERIOSCLEROSIS OBLITERANS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33745964003     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular disease in man. J Pharm Pharmacol 1983;35:666-7.
2. Fukuhara S, Esato K. The effect of Liple® on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. Int Angiol 2004;23:238-45.
3. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
4. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11:341-53.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. 1st ed. New York: Oxford University Press; 1996.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
7. Nawata S, Yamada Y, Ikeda S, Ikegami N. [EuroQol study of the elderly general population: relationship with IADL and other attitudes]. Iryo to Shakai 2000;10:75-85.
8. Diehm C, Balzer K, Bisler H, Bulling B, Camci M, Creutzig A et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997;25:537-44.
9. Creutzig A, Bullinger M, Cachovan M, Diehm C, Forst HT, Grass JD et al. Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication. Vasa 1997;26:122-7.
10. Gruss JD. Effect of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results. Vasa 1997;26:117-21.
11. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. Circulation 1994;90:818-22.
12. Hirth R, Chernew M, Miller E, Fendrick A, Weissert W, Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42.